Published: December 16, 2021 20:58:17 | Updated: December 21, 2021 16:38:40
AstraZeneca on Thursday said a lab-study of its COVID-19 antibody cocktail, Evusheld, found that the treatment retained neutralising activity against the omicron coronavirus variant, showing promise for wider use of the therapy.
The study was conducted by independent investigators of the US Food and Drug Administration, reports Reuters.
The company said that more analyses of Evusheld against omicron are being conducted by AstraZeneca and third-parties, with data expected "very soon".
Moderna to make milestone payments to US for Covid-19 vaccine
Bird flu situation 'worrying', WHO working with Cambodia
A woman dies every two minutes due to pregnancy or childbirth: UN report
Oral dose of azithromycin at normal birth can reduce 33pc maternal sepsis and deaths: Study
Can topical treatment alone fix acne scars?
Vitamin A-plus campaign for 22.0 million children held
Why the success of making an artificial heart remains elusive?
No specific research on zinc level in rice
© 2024 - All Rights with The Financial Express
